

Organizing committee

Gaetano Finocchiaro, phone 02 23942454/ 349 0795665
National Neurological Institute "Carlo Besta", Milan, Italy
gaetano.finocchiaro@gmail.com

Lucia Cuppini, phone 02 23942285
National Neurological Institute "Carlo Besta", Milan, Italy
lucia.cuppini@gmail.com

Serena Pellegatta, phone 02 23942285
National Neurological Institute "Carlo Besta", Milan, Italy
serenapellegatta@gmail.com

Sabrina Frata, phone 02 574303296
SEMM Foundation, Milan, Italy
sabrina.frata@semm.it

Alessandra Giovannini, phone 051 6460421

Elena Torchiana, phone 348 3519605
Miltenyi Biotec S.r.l.
macs.simposi@miltenyibiotec.it
Fax: 051 6460499

For more information, please visit:
www.semm.it/meeting/brain07

Congress venue

IFOM-IEO Campus
Via Adamello, 16
Milan, Italy

How to get to the IFOM-IEO Campus

From the Stazione Centrale:

Take the Underground line 3, bound for San Donato, to Crocetta (6 stops). Then, take tram no. 24, bound for Vigentino, to Ripamonti-Serio (6 stops). Walk down Via Serio until it junctions with Via Adamello. Turn left; the IFOM-IEO Campus will be on the left after 20 meters.

By car:

Once on the Eastern Ring Road, take the Piazzale Corvetto exit. At Piazzale Corvetto, turn onto the Corso Lodi. Further down, turn left onto the Viale Brenta and then take the Viale Ortles from the Piazza Bonomelli. At the junction with Via Condino, turn right and continue straight on until you reach the Via Adamello.



Miltenyi Biotec

Miltenyi Biotec S.r.l. (Italy)

Phone 051 6 46 04 11

Fax 051 6 46 04 99

macs@miltenyibiotec.it

REGISTRATION

Brain Tumor Immunotherapy

An International Symposium

IFOM-IEO Campus
October 19, 2007

There is no admission fee. The number of participants is limited, so a maximum of three people from each group will be accepted.

Please subscribe by **e-mail macs.simposi@miltenyibiotec.it** or by **fax 051 6460499** to the organizing secretariat **before October 9, 2007**.

Only people receiving e-mail confirmation on **October 12, 2007** are allowed to participate (please specify your e-mail address).

On-site subscriptions will not be accepted.



Unless otherwise specifically indicated, all Miltenyi Biotec products and services are for research use only and not for diagnostic or therapeutic use. MACS is a registered trademark of Miltenyi Biotec GmbH.

www.miltenyibiotec.com



FONDAZIONE I.R.C.C.S ISTITUTO
NEUROLOGICO "CARLO BESTA"
ISTITUTO DI RICOVERO E CURA A CARATTERE
SCIENTIFICO DI NATURA PUBBLICA



UNIVERSITÀ
DEGLI STUDI
DI MILANO



Brain Tumor Immunotherapy

An International Symposium

IFOM-IEO Campus
Milan

October 19, 2007

Part of MACS® Symposia 2007

Organized by Gaetano Finocchiaro
in collaboration with Miltenyi Biotec



Miltenyi Biotec

TOPICS

- Central Nervous System
- Neuro-oncology
- Immunotherapy
- Dendritic cells
- Cancer stem cells

The horizon for cancer immunotherapy has been broadened by recent acquisitions in the biology of dendritic cells and by research on the role of T regulatory cells in the escape of cancer from the immune system. Brain tumors are an excellent arena for the development of this progress. Malignant gliomas, in particular, are the subject of novel trials and initial experiences have been gained with dendritic cell immunotherapy. Moreover, new insights on the role of cancer stem-like cells in glioma development may help to define more specific targets for clinically relevant immune responses.

CHAIRPERSONS

Filippo Belardelli

Istituto Superiore di Sanità, Rome, Italy

Amerigo Boiardi

National Neurological Institute "Carlo Besta", Milan, Italy

Giovanni Broggi

National Neurological Institute "Carlo Besta", Milan, Italy

I. Jolanda M. de Vries

NCMLS, RUNMC, Nijmegen, The Netherlands

Gaetano Finocchiaro

National Neurological Institute "Carlo Besta", Milan, Italy

Renato Mantegazza

National Neurological Institute "Carlo Besta", Milan, Italy

Maura Massimino

Istituto Nazionale dei Tumori, Milan, Italy

Stefaan van Gool

Pediatric Hemato-oncology and Neuro-oncology, University Hospital Gasthuisberg, Leuven, Belgium

SPEAKERS

Francesca Aloisi

Istituto Superiore di Sanità, Rome, Italy

Federica Cavallo

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy

Mario P. Colombo

Istituto Nazionale Tumori, Milan, Italy

Steven De Vleeschouwer

University Hospital Leuven, Catholic University Leuven, Belgium

I. Jolanda M. de Vries

NCMLS, RUNMC, Nijmegen, The Netherlands

Paolo Ferroli

National Neurological Institute "Carlo Besta", Milan, Italy

Gaetano Finocchiaro

National Neurological Institute "Carlo Besta", Milan, Italy

Amy Heimberger

The Brain Tumor Center, The University of Texas, Houston, Texas, U.S.A.

Serena Pellegatta

National Neurological Institute "Carlo Besta", Milan, Italy

Maria Rescigno

IEO, Milan, Italy

John H. Sampson

Duke University Medical Center, Durham, N.C., U.S.A.

Rüdiger V. Sorg

Heinrich-Heine-University Hospital, Düsseldorf, Germany

Stefaan van Gool

Pediatric Hemato-oncology and Neuro-oncology, University Hospital Gasthuisberg, Leuven, Belgium

SCIENTIFIC PROGRAM

8.30–9.00 Registration of participants

MORNING SESSION

Chair: Renato Mantegazza and Stefaan van Gool

9.00–9.35 "Are oncoantigens suitable targets for anti-tumor therapy?"

Federica Cavallo

9.35–10.10 "Bacteria as a tool to initiate systemic anti-tumor responses"

Maria Rescigno

10.10–10.45 "Inhibiting Tregs activity in tumor bearers"

Mario P. Colombo

10.45–11.00 Coffee break

Chair: Filippo Belardelli and Jolanda de Vries

11.00–11.35 "Innate immunity in the central nervous system"
Francesca Aloisi

11.35–12.10 "Surgery in the context of treatments for malignant gliomas"
Paolo Ferroli

12.10–12.45 "Cancer stem cells and the biology of malignant gliomas"
Gaetano Finocchiaro

12.45–13.30 Lunch

AFTERNOON SESSION

Chair: Giovanni Broggi and Gaetano Finocchiaro

13.30–14.05 "Dendritic cell immunotherapy in cancer patients"
I. Jolanda M. de Vries

14.05–14.40 "The EGFRvIII clinical vaccine and regulatory T cells"
John H. Sampson

14.40–15.15 "Generation of dendritic cell vaccines in glioma patients and interference of glioma cells with dendritic cell-based immunity"
Rüdiger V. Sorg

15.15–15.50 "STAT-3 and its role in immunity"
Amy Heimberger

15.50–16.10 Coffee break

Chair: Maura Massimino and Amerigo Boiardi

16.10–16.45 "New developments for dendritic cell immunotherapy: Intra-tumoral injection of dendritic cells and targeting of cancer stem-like cells"
Serena Pellegatta

16.45–17.20 "Dendritic cell vaccination in malignant glioma: Current status and (presumed) future directions"
Steven De Vleeschouwer

17.20–17.40 "Final overview"
Stefaan van Gool